Giorgio Quadri1*, MD; Fabrizio D’Ascenzo1, MD; Claudio Moretti1, MD; Maurizio D’Amico1, MD; Sergio Raposeiras-Roubín2, MD; Emad Abu-Assi2, MD; Jose Paulo Simao Henriques3, MD; Jorge Saucedo4, MD; José Ramón González-Juanatey5, MD; Stephen B. Wilton6, MD; Wouter J. Kikkert3, MD; Iván Nuñez-Gil7, MD; Albert Ariza-Sole8, MD; Xiantao Song9, MD; Dimitrios Alexopoulos10, MD; Christoph Liebetrau11, MD; Tetsuma Kawaji12, MD; Zenon Huczek13, MD; Shao-Ping Nie
1. Dipartimento di Scienze Mediche, Divisione di Cardiologia, Città della Salute e della Scienza, Turin, Italy; 2. University Hospital Álvaro Cunqueiro, Vigo, Spain; 3. University Academic Medical Center, Amsterdam, the Netherlands; 4. NorthShore Universi
Aims: The benefit of complete or incomplete percutaneous coronary intervention (PCI) in patients with myocardial infarction and multivessel disease remains debated. The aim of our study w
No account yet?
Sign up for free!
Create my pcr account
Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases
from PCRonline.com
multiple vessel diseasenon-st-segment elevation myocardial infarction (nstemi)st-segment elevation myocardial infarction (stemi)
Coronary interventionsSTEMINSTEMILeft main and multivessel diseaseVascular access and bleedingVascular access and bleedingVascular access and bleeding
Read next article
First-in-human evaluation of a novel poly-L-lactide based sirolimus-eluting bioresorbable vascular scaffold for the treatment of de novo native coronary artery lesions: MeRes-1 trial